Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

GLP-1 therapy is a groundbreaking approach in the treatment of obesity and metabolic health issues. GLP-1, or glucagon-like ...

GLP-1RAs, a class of glucose-lowering medication used to treat diabetes and obesity, may offer antidepressant effects. UF ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Health experts are concerned Ozempic and other GLP-1 agonist drugs may be inappropriately prescribed to people experiencing disordered eating.

Harbour BioMed launches Élancé Therapeutics to advance next-generation obesity therapies: Cambridge, Massachusetts Thursday, March 13, 2025, 18:00 Hrs [IST] Harbour BioMed, a gl ...

Evoke Pharma, Inc. ( NASDAQ: EVOK) Q4 2024 Earnings Conference Call March 13, 2025 4:30 PM ET Daniel Kontoh-Boateng – DKB Partners Matt D’Onofrio – Chief Executive Officer Chris Quesenberry – Chief ...

Q4 2024 Earnings Call Transcript March 12, 2025 Amarin Corporation plc beats earnings expectations. Reported EPS is $-0.03, ...

Discover how drinking black coffee can boost your mood, fight cancer, reduce disease risk, and improve overall health in ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...